Book Chapter

An G and Morris ME, Enzyme- and Transporter-Based Drug-Drug Interactions- Progress and Future Challenge, book edited by Pang KS, Rodrigues AD and Peter RM. Springer 2010, pp.555-584.

Peer Reviewed Articles

  1. Bi Y, Deng J, Murry DJ, An G*. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. AAPS J. 2015 Nov 11. [Epub ahead of print] * Corresponding author.(PubMed link)

  2. Ma B, Qi H, Li J, Xu H, Chi B, Zhu J, Yu L, An G, Zhang Q. Triptolide disrupts fatty acids and peroxisome proliferator-activated receptor (PPAR) levels in male mice testes followed by testicular injury: A GC-MS based metabolomics study. Toxicology. 2015;336:84-95(PubMed link)

  3. An G*, Kaur Mukker J, Derendorf H, Frye RF. Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea. Journal of Clinical Pharmacology 2015 Jun 10. [Epub ahead of print].* Corresponding author.(PubMed link)

  4. Ziegler D, Duan WR, An G, Thomas JW, Nothaft W. A randomized double-blind, placebo- and active-controlled study of T-type calcium channel blocker ABT-639 in diabetic patients with peripheral neuropathic pain. Pain 2015;156(10):2013-20.(PubMed link)

  5. An G*, Liu W, Dutta S. Small molecule compounds exhibiting target-mediated drug disposition (TMDD) - a case example of ABT-384. Journal of Clinical Pharmacology 2015;55(10):1079-85.* Corresponding author.(PubMed link)

  6. Alsultan A, An G, Peloquin CA. Limited Sampling Strategy and Target Attainment Analysis for Levofloxacin in Patients with Tuberculosis.Antimicrob Agents Chemother. 2015;59(7):3800-7.(PubMed link)

  7. Cope JM, Bushwitz J, An G, Antigua A, Patel A, Zumberg M. Reply: clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy.Ann Pharmacother 2015;49(5):614-5.(PubMed link)

  8. An G*, Liu W, Duan WR, Nothaft W, Awni W, Dutta S. Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers. AAPS J. 2015;17(2):481-92. * Corresponding author.(PubMed link)

  9. Bei D and An G*. Quantification of 5,7-Dimethoxyflavone in Mouse Plasma using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and its Application to a Pharmacokinetic Study. Journal of Chromatography B 2015 Jan; 978-979:11-7. * Corresponding author.(PubMed link)

  10. Fleisher B, Uum J, Shao J, and An G*. Ingredients in Fruit Juice Interact with Dasatinib through Inhibition of BCRP: A New Mechanism of Beverage-Drug Interaction. Journal of Pharmaceutical Sciences 2015 Jan;104(1):266-75 * Corresponding author.(PubMed link)

  11. Cope J, Bushwitz J, An G, Antigua A, Patel A, and Zumberg M. Clinical experience with fondaparinux in critically ill patients with moderate to severe renal impairment and renal failure requiring renal replacement therapy. Annals of Pharmacotherapy 2015 ;49(3):270-7(PubMed link)

  12. Egelund EF, Isaza R, Brock AP, Alsultan A, An G, and Peloquin CA. Population Pharmacokinetics of Rifampin in the Treatment of Mycobacterium Tuberculosis in Elephants. Journal of Veterinary Pharmacology and Therapeutics 2015;38(2):137-43(PubMed link)

  13. Shao J, Markowitz JS, Bei D, and An G*. Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 2014 Dec;103(12):3810-33 * Corresponding author.(PubMed link)

  14. An G*, Liu W, Katz D, Marek G, Awni W, and Dutta S. Population Pharmacokinetics of the Potent, Selective 11ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers following Single and Multiple Dose Regimens. Biopharmaceutics & Drug Disposition 2014 Oct;35(7):417-29. * Corresponding author (PubMed link)

  15. An G#, Wang X#, and Morris ME. Flavonoids are Inhibitors of Human Organic Anion Transporter 1 (OAT1). Drug Metabolism and Disposition 2014;42(9):1357-66. # contributed equally (PubMed link)

  16. Deng J, Shao J, Markowitz JS, and An G*. ABC Transporters in the Multi-drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors. Pharmaceutical Research 2014; 31 (9):2237-55 * Corresponding author. (PubMed link)

  17. Katz DA, Liu W, Locke C, Jacobson P, Barnes DM, Basu R, An G, Rieser MJ, Daszkowski D, Groves F, Henegh, Shah A, Gevorkyan H, Jhee SS, Ereshefsky L, Marek GJ. Peripheral and central nervous system inhibition of 11?-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384. Translational Psychiatry 2013; 3:e295, 1-7.(PubMed link)

  18. An G*, Liu W, Katz D, Marek G, Awni W, and Dutta S. Effect of Ketoconazole on the Pharmacokinetics of ABT-384 and Its Two Active Metabolites in Healthy Volunteers: Population Analysis of Data from a Drug-Drug Interaction Study. Drug Metabolism and Disposition 2013; 41(5): 1035-45. * Corresponding author(PubMed link)

  19. An G and Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. The AAPS Journal 2012; 14(2):352-64.(PubMed link)

  20. Tsiklauri L, An G, Alaniya M, Kemertelidze E, Morris ME. Optimal Parameters of HPLC for Simultaneous Determination Robinin and Kaempferol. Pharmaceutical Chemistry Journal 2012,46(1):49-52.

  21. An G and Morris ME. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). Biopharmaceutics & Drug Disposition 2011; 32(8):446-457.(PubMed link)

  22. An G, Wu F, and Morris ME. 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice. Pharmaceutical Research 2011;28(5):1090-9.(PubMed link)

  23. An G, Gallegos J, and Morris ME. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metabolism & Disposition 2011;39(3):426-32.(PubMed link)

  24. Tsiklauri L, An G, Ruszaj DM, Alaniya M, Kemertelidze E, Morris ME. Simultaneous determination of the flavonoids robinin and kaempferol in human breast cancer cells by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2011,55(1):109-13.(PubMed link)

  25. An G and Morris ME. Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro. Pharmaceutical Research 2010;27(7): 1296-308.(PubMed link)

  26. An G, Ruszaj DM, and Morris ME. Interference of a sulfate conjugate in quantitative liquid chromatography/tandem mass spectrometry through in-source dissociation. Rapid Communications in Mass Spectrometry 2010; 24:1817-1819.(PubMed link)

  27. An G and Morris ME. The effect of isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharmaceutics & Drug Disposition 2010; 31:340-350.(PubMed link)

  28. An G and Morris ME. HPLC analysis of mitoxantrone in mouse plasma and tissues: Application in a pharmacokinetic study. J Pharm Biomed Anal 2010; 51(3): 750-3.(PubMed link)

  29. Moon YJ, Shin BS, An G and Morris ME. Biochanin A inhibits breast cancer tumor growth in a murine xenograft model. Pharmaceutical Research 2008; 25(9): 2158-63.(PubMed link)

  30. Yu Z, Chen B, Zhang W, Fang J, An G and Cai WM. Relative bioavailability and bioequivalence of ibuprofen orally disintegrating tablets in healthy volunteers. Chinese Journal of Clinical Pharmacy 2006;15(5): 280-283.

  31. Yu Z, Zhou P, Wang X, Xu D, Chen B, Zhang W, An G and Fang J. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult Chinese renal recipients. Chinese Journal of Clinical Pharmacology 2006;22(6): 243-247.

  32. Yu Z, Chen B, Zhang W, An G, Fang J, and Cai WM. Pharmacokinetics of Pazufloxacin Mesilate in Chinese Healthy Volunteers. Chinese Pharmaceutical Journal 2006; 41(15): 1168-1171.

  33. Di Q, Zhu B, An G, and Cai WM. The application status and future trend of parenteral nutrition preparation. China Pharmacy 2005; 16(11): 862-863

  34. An G, Ji MC, Geng XF, and Cheng NN. The cost-effective analysis of different antihyperglycemic therapies in patients with type 2 diabetes mellitus. Chinese Journal of Hospital Pharmacy J 2004; 24(7):423-424.

  35. An G, Geng XF, and Ji MC. Interactions of antihyperglycemic agents and drugs, Chinese Journal of Clinical Pharmacology 2003; 19(1): 67-70.

  36. An G, Geng XF, and Ji MC. Prescribing patterns and therapeutic implications in a cohort of 200 outpatients with type 2 diabetes and hypertension. Chinese Journal of Pharmacoepidemiology 2003; 12(2): 80-82.

  37. Ji MC, Geng XF, and An G. The rational drug use analysis in insomniac patients in comprehensive hospital. Chinese Academic Medical Magazine of Organisms 2002; 3:38-41.

  38. An G, Geng XF, and Ji MC. The application of evidence-based medicine in the drug therapy of type 2 Diabetes Mellitus. Chinese Academic Medical Magazine of Organisms 2002; 3: 57-59.

Abstracts

1. Bae S, D’Cunha R, and An G. Exploring the Synergy of TKIs Combination Therapy – A Pilot Study of Transporter-mediated Interaction between Dasatinib and Other TKIs in Vitro. ICRU, Iowa City, Nov 18, 2015

2. Awasthi R, An G, Donovan M, and Ponto L. An Effect-Compartment Modeling Approach to Relate the Plasma Concentrations of Delta-9-Tetrahydrocannabinol (THC) and Active Metabolite to the Observed Psychoactive Effects. AAPS, Orlando, Oct 25-29, 2015

3. Fleisher B, Uum J, Shao J, and An G. Grapefruit Juice Ingredients Interact with Dasatinib through Inhibition of Breast Cancer Resistance Protein (BCRP): A New Type of Beverage-Drug Interaction. ASCPT, 2015

4. Uum J, Fleisher B, Shao J, and An G. Orange Juice and Apple Juice Ingredients Inhibit Dasatinib Efflux via P-Glycoprotein and Breast Cancer Resistance Protein: A New Type of Beverage-Drug Interaction. ASCPT, 2015

5. Bei D and An G. Quantification of 5,7-Dimethoxyflavone in Mouse Plasma using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and its Application to a Pharmacokinetic Study. AAPS, 2014

6. Alsultan A, Derby R, An G, and Peloquin C. Bayesian Estimation of Levofloxacin Pharmacokinetics in Patients with Tuberculosis. ICAAC, 2014.

7. Tsiklauri L.K., An G, Tsagareishvili G.V., Alaniya M, Kemertelidze E, Morris M.E. Investigation of Functional Role of Membrane Transporters in Oral Bioavailability of Robinin. III International Scientifi c and Practical Conference “Topical issues in medicine”, West Kazakhstan Marat Ospanov State Medical University. Aktobe, Kazakhstan, April 17-18, 2014

8. Gottipati G, Lin C, Venitz J, Lesko L, and An G. Model-based Meta-analysis (MBMA) of Adverse Events (AE) and Dropouts (DO) for Drugs Evaluated for the Treatment of Fibromyalgia pain (FMP), ASCPT, Atlanta, Mar 18-21, 2014.

9. Gottipati G, Trame, MN, Lin C, Venitz J, Lesko L, and An G. Model-based Meta-analysis (MBMA) of Efficacy at End-of-Trial and Efficacy-Time Course for Drugs Evaluated for the Treatment of Fibromyalgia pain (FMP). ASCPT, Atlanta, Mar 18-21, 2014. [Gottipati received Presidential Trainee Award for this poster].

10. Deng J, Lesko L, and An G. A Physiologically Based Pharmacokinetic Model of Gefitinib Disposition: from Rat to Man. ASCPT, Atlanta, Mar 18-21, 2014.

11. Deng J, Lesko L, and An G. Prediction of Gefitinib Human Pharmacokinetics From Animal Data - Comparative Assessment of Different Allometric Scaling Approaches. ASCPT, Atlanta, Mar 18-21, 2014.

12. Shao J*, Deng J*, Bei D, and An G. Nilotinib is a dual P-gp and BCRP inhibitor and inhibits P-gp-mediated dasatinib efflux and BCRP-mediated gefitinib efflux. (*contributed equally) UF Health Cancer Center Research Poster Day. Gainesville, Mar 11, 2014

13. Shao J, Deng J, Bei D, and An G. Exploring the Synergy of TKIs Combination Therapy – A Pilot Study of P-gp-mediated Interaction between Dasatinib and Imatinib in LLC PK1 Cells. UF COP Research Showcase. Gainesville, Feb 20, 2014.

14. Cope J, Antigua A, Bushwitz J, An G, Patel A, and Zumberg M. Fondaparinux Use in Severe Renal Impairment and Renal Failure Requiring Renal Replacement Therapy. Society of Critical Care Medicine Annual Congress. San Francisco, January 9-13, 2014.

15. Deng J, Lesko L, and An G. A Physiologically Based Pharmacokinetic Model of Gefitinib Disposition: from Rat to Man. Graduate Research Day, Gainesville, Oct 31st, 2013.

16. Deng J, Jiang XL, Schmidt S, Lesko L, and An G. Physiologically-Based Pharmacokinetic Model for the CYP3A-mediated Inhibition of Midazolam Inhibition by Itraconazole. 9th Retrometabolism Based Drug Design and Targeting Conference, Orlando, May 12-15, 2013.

17. An G*, Wang X*, and Morris ME. Dietary Flavonoid Fisetin is a Substrate and Inhibitor of Human Organic Anion Transporter 1 (OAT1). (* contributed equally) AAPS, Chicago, Oct 14-18, 2012.

18. An G, Liu W, Awni W, and Dutta S. Model-Based Meta-Analyses of Efficacy and Safety of COX-2 Inhibitors in Patients with Osteoarthritis Pain. AAPS, Chicago, Oct 14-18, 2012.

19. Liu W, An G, Dutta S, Nothaft W, Duan R, Jain R, Awni W. ABT-652 Phase 2b Dose Selection Based on Exposure-Response Analyses of Efficacy, Safety (Heart Rate, Adverse Effects) and Dropout from Proof of Concept Study in Subjects with Osteoarthritic Pain. Abbott Day of Science and Technology, Chicago, Nov 14-15, 2011.

20. An G and Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice: a mechanism-based model incorporating DNA and protein binding. ACoP, San Diego, April 3-6, 2011

21. An G and Morris ME. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. AAPS, New Orleans, Nov 14-18, 2010

22. An G and Morris ME. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). AAPS, New Orleans, Nov 14-18, 2010

23. An G and Morris ME. A PBPK model of mitoxantrone in mice: a mechanism-based model incorporating macromolecule binding. Pharmacology Day, University at Buffalo, July 27, 2010

24. An G and Morris ME. Determination of mitoxantrone in mouse plasma and tissues by an improved HPLC method and its application in a pharmacokinetic study. AAPS, Los Angeles, Nov 7-11, 2009

25. An G and Morris ME. Transport and efflux of quercetin and biochanin A in MDCK cell monolayers- role of efflux transporters. AAPS, Los Angeles, Nov 7-11, 2009

26. Liu JH, An G and Morris ME. The effect of flavonoids on transport of mitoxantrone in ABCG2 transfected MDCK cells. Sigma Xi, University at Buffalo, April, 2009

27. An G and Morris ME. Inhibition of the BCRP-mediated transport of mitoxantrone by the flavonoids Biochanin A and Kaempferide. AAPS, Atlanta, Nov7-11, 2008.

28. An G and Morris ME. Effect of multiple flavonoid combinations on Breast Cancer Resistance Protein (ABCG2) mediated transport. AAPS, Atlanta, Nov 7-11, 2008